SG11201701565PA - Conjugates comprising cell-binding agents and cytotoxic agents - Google Patents
Conjugates comprising cell-binding agents and cytotoxic agentsInfo
- Publication number
- SG11201701565PA SG11201701565PA SG11201701565PA SG11201701565PA SG11201701565PA SG 11201701565P A SG11201701565P A SG 11201701565PA SG 11201701565P A SG11201701565P A SG 11201701565PA SG 11201701565P A SG11201701565P A SG 11201701565PA SG 11201701565P A SG11201701565P A SG 11201701565PA
- Authority
- SG
- Singapore
- Prior art keywords
- agents
- conjugates
- cell
- cytotoxic
- binding
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 239000002254 cytotoxic agent Substances 0.000 title 1
- 231100000599 cytotoxic agent Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462045264P | 2014-09-03 | 2014-09-03 | |
US201462086986P | 2014-12-03 | 2014-12-03 | |
US201562149379P | 2015-04-17 | 2015-04-17 | |
US201562186235P | 2015-06-29 | 2015-06-29 | |
PCT/US2015/048044 WO2016036794A1 (fr) | 2014-09-03 | 2015-09-02 | Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201701565PA true SG11201701565PA (en) | 2017-03-30 |
Family
ID=54147280
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701565PA SG11201701565PA (en) | 2014-09-03 | 2015-09-02 | Conjugates comprising cell-binding agents and cytotoxic agents |
SG10201901825YA SG10201901825YA (en) | 2014-09-03 | 2015-09-02 | Conjugates comprising cell-binding agents and cytotoxic agents |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201901825YA SG10201901825YA (en) | 2014-09-03 | 2015-09-02 | Conjugates comprising cell-binding agents and cytotoxic agents |
Country Status (13)
Country | Link |
---|---|
US (2) | US10988531B2 (fr) |
EP (1) | EP3188733B1 (fr) |
JP (1) | JP2017529837A (fr) |
KR (3) | KR20240027148A (fr) |
CN (1) | CN107580604A (fr) |
AU (1) | AU2015312075A1 (fr) |
CA (1) | CA2957964A1 (fr) |
IL (1) | IL250711A0 (fr) |
MA (1) | MA40415A (fr) |
RU (1) | RU2017110068A (fr) |
SG (2) | SG11201701565PA (fr) |
TW (1) | TW201609152A (fr) |
WO (1) | WO2016036794A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016036861A1 (fr) * | 2014-09-02 | 2016-03-10 | Immunogen, Inc. | Procédés de formulation de compositions de conjugués anticorps-médicaments |
TW201609152A (zh) | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
TWI697493B (zh) * | 2014-09-03 | 2020-07-01 | 美商免疫原公司 | 細胞毒性苯并二氮呯衍生物 |
IL282614B2 (en) | 2015-02-06 | 2024-02-01 | Cell Idx Inc | Antigen-conjugated immune reagents |
HUE053619T2 (hu) * | 2015-06-29 | 2021-07-28 | Immunogen Inc | Anti-CD123 antitestek és konjugátumok és ezek származékai |
US10081640B2 (en) | 2015-07-21 | 2018-09-25 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
EA201891723A1 (ru) * | 2016-02-05 | 2018-12-28 | Милленниум Фармасьютикалз, Инк. | Gcc-направленные конъюгаты антитело-лекарство |
TWI750194B (zh) * | 2016-07-05 | 2021-12-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | Egfr抗體-藥物偶聯物及其在醫藥上的應用 |
JP2019532019A (ja) * | 2016-07-22 | 2019-11-07 | ネクター セラピューティクス | オキシム含有リンケージを有する第viii因子部分のコンジュゲート |
MA46779A (fr) * | 2016-11-02 | 2019-09-11 | Health Research Inc | Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp |
HUE058664T2 (hu) * | 2016-12-23 | 2022-09-28 | Immunogen Inc | ADAM9-et célzó immunkonjugátumok és eljárások azok felhasználására |
CN116785450A (zh) * | 2017-02-28 | 2023-09-22 | 伊缪诺金公司 | 具有自分解肽接头的类美登素衍生物和其缀合物 |
WO2018183494A1 (fr) * | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Conjugués anticorps-médicament ciblant cd19 |
AU2018305726B2 (en) * | 2017-07-26 | 2022-09-15 | The University Of Queensland | Disulfide bond containing compounds and uses thereof |
CN116999573A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体-药物偶联物及其制造方法、药物组合物及其在制备治疗肿瘤的药物中的应用 |
CN111601824A (zh) * | 2017-11-21 | 2020-08-28 | 诺华股份有限公司 | 针对肿瘤相关抗原的三特异性结合分子及其用途 |
CN111587125A (zh) * | 2018-01-12 | 2020-08-25 | 伊缪诺金公司 | 抗体药物缀合、纯化和调配的方法 |
CA3091683A1 (fr) | 2018-03-13 | 2019-09-19 | Phanes Therapeutics, Inc. | Anticorps anti-recepteur 1 aux folates et leurs utilisations |
WO2020016661A2 (fr) * | 2018-07-09 | 2020-01-23 | Multitude Inc. | Anticorps spécifiques du récepteur alpha du folate |
WO2020092631A1 (fr) * | 2018-10-31 | 2020-05-07 | Fred Hutchinson Cancer Research Center | Compositions et méthodes de détection et de traitement de cancers caractérisés par l'expression de la mésothéline |
US20210032285A1 (en) * | 2019-03-11 | 2021-02-04 | Cell Idx, Inc. | Methods, compositions, and kits for trapping modified biomolecules |
CA3133155A1 (fr) | 2019-03-19 | 2020-09-24 | Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron | Polytherapie pour le traitement du cancer |
CN113631194A (zh) * | 2019-03-21 | 2021-11-09 | 伊缪诺金公司 | 制备细胞结合剂-药物缀合物的方法 |
CN110922482B (zh) * | 2019-12-25 | 2021-08-31 | 源道隆(苏州)医学科技有限公司 | 可结合cd19的多肽及其应用 |
CN112794911B (zh) * | 2021-04-14 | 2021-08-03 | 上海偌妥生物科技有限公司 | 人源化抗叶酸受体1抗体及其应用 |
CN113908589B (zh) * | 2021-10-08 | 2022-09-27 | 天津工业大学 | 一种表面印迹抗体的疏水电荷诱导模式膜层析介质及其制备方法 |
WO2024089013A1 (fr) | 2022-10-25 | 2024-05-02 | Peptomyc, S.L. | Polythérapie pour le traitement du cancer |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
FR2801904B1 (fr) | 1999-12-07 | 2002-02-08 | Pasteur Institut | Produits comprenant un support sur lequel sont fixes des acides nucleiques et leur utilisation comme puce a adn |
US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
DE60310958T2 (de) | 2002-09-19 | 2007-10-11 | Centre National De La Recherche Scientifique (Cnrs) | Synthese und charakterisierung neuer systeme zum hinführen und zur vektorisierung von molekülen von therapeutischem interesse zu targetzellen |
WO2004060299A2 (fr) | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Conjugues polymeres d'interferon-beta presentant une activite biologique accrue |
GB0305704D0 (en) | 2003-03-13 | 2003-04-16 | Amersham Plc | Radiofluorination methods |
US20080182783A1 (en) | 2004-10-18 | 2008-07-31 | Novo Nordisk A/S | Growth Hormone Conjugates |
WO2006094813A2 (fr) | 2005-03-10 | 2006-09-14 | Nascacell Technologies Ag. | Microproteines dimeriques ou multimeriques |
WO2006115416A2 (fr) | 2005-04-25 | 2006-11-02 | Ge Healthcare As | Liposomes |
JP4938263B2 (ja) * | 2005-08-19 | 2012-05-23 | 独立行政法人農業生物資源研究所 | 一本鎖抗体によるサイトゾルタンパク質の機能阻害法およびその利用 |
CA2630415A1 (fr) | 2005-10-20 | 2007-04-26 | The Scripps Research Institute | Marquage de parties fc pour l'immunocoloration et l'immunociblage |
FR2897616B1 (fr) | 2006-02-20 | 2008-05-30 | Univ Grenoble 1 | Presentation de motifs de reconnaissance par une matrice multivalente greffee sur un support solide |
US7985783B2 (en) * | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
PE20140614A1 (es) | 2007-07-16 | 2014-05-28 | Genentech Inc | Anticuerpos anti-cd79b e inmunoconjugados |
EP2211904B1 (fr) | 2007-10-19 | 2016-08-17 | Seattle Genetics, Inc. | Agents de liaison au cd19 et utilisations de ceux-ci |
US20090181037A1 (en) * | 2007-11-02 | 2009-07-16 | George Heavner | Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses |
EP2276506A4 (fr) * | 2008-04-30 | 2014-05-07 | Immunogen Inc | Conjugués puissants et coupleurs hydrophiles |
SG10201501342UA (en) * | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
US9381058B2 (en) * | 2010-11-05 | 2016-07-05 | Ethicon Endo-Surgery, Llc | Recharge system for medical devices |
RU2748733C2 (ru) * | 2011-02-15 | 2021-05-31 | Иммуноджен, Инк. | Цитотоксические производные бензодиазепина |
MX2014012889A (es) * | 2012-05-01 | 2014-11-14 | Genentech Inc | Anticuerpos e inmunoconjugados anti-pmel17. |
JP5868549B2 (ja) * | 2012-05-24 | 2016-02-24 | マウントゲイト グループ リミテッド | 狂犬病感染の予防および治療に関する組成物および方法 |
MX2014014683A (es) | 2012-06-06 | 2015-02-24 | Bionor Immuno As | Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion. |
US9834597B2 (en) | 2012-09-21 | 2017-12-05 | The Regents Of The University Of California | Modified FC polypeptides, FC conjugates, and methods of use thereof |
WO2014156159A1 (fr) * | 2013-03-28 | 2014-10-02 | 東芝ホクト電子株式会社 | Dispositif électroluminescent et son procédé de fabrication |
US9636404B2 (en) | 2013-05-13 | 2017-05-02 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
CN105814079B (zh) * | 2013-08-30 | 2021-02-09 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
EA201691075A1 (ru) | 2013-11-26 | 2016-09-30 | Новартис Аг | Способы оксимной конъюгации с кетон-модифицированными полипептидами |
TW201609152A (zh) | 2014-09-03 | 2016-03-16 | 免疫原公司 | 包含細胞結合劑及細胞毒性劑之偶聯物 |
-
2015
- 2015-09-02 TW TW104128984A patent/TW201609152A/zh unknown
- 2015-09-02 MA MA040415A patent/MA40415A/fr unknown
- 2015-09-02 KR KR1020247005372A patent/KR20240027148A/ko active Application Filing
- 2015-09-02 EP EP15766288.3A patent/EP3188733B1/fr active Active
- 2015-09-02 KR KR1020177009020A patent/KR102508023B1/ko active IP Right Grant
- 2015-09-02 CA CA2957964A patent/CA2957964A1/fr not_active Abandoned
- 2015-09-02 US US14/843,429 patent/US10988531B2/en active Active
- 2015-09-02 RU RU2017110068A patent/RU2017110068A/ru not_active Application Discontinuation
- 2015-09-02 KR KR1020237007792A patent/KR102638901B1/ko active IP Right Grant
- 2015-09-02 AU AU2015312075A patent/AU2015312075A1/en not_active Abandoned
- 2015-09-02 JP JP2017512760A patent/JP2017529837A/ja active Pending
- 2015-09-02 WO PCT/US2015/048044 patent/WO2016036794A1/fr active Application Filing
- 2015-09-02 SG SG11201701565PA patent/SG11201701565PA/en unknown
- 2015-09-02 CN CN201580059534.4A patent/CN107580604A/zh active Pending
- 2015-09-02 SG SG10201901825YA patent/SG10201901825YA/en unknown
-
2017
- 2017-02-22 IL IL250711A patent/IL250711A0/en unknown
-
2021
- 2021-02-12 US US17/174,911 patent/US11732038B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2016036794A1 (fr) | 2016-03-10 |
CA2957964A1 (fr) | 2016-03-10 |
KR102508023B1 (ko) | 2023-03-10 |
US20210299271A1 (en) | 2021-09-30 |
MA40415A (fr) | 2016-03-10 |
CN107580604A (zh) | 2018-01-12 |
KR102638901B1 (ko) | 2024-02-22 |
KR20230039755A (ko) | 2023-03-21 |
JP2017529837A (ja) | 2017-10-12 |
AU2015312075A1 (en) | 2017-03-09 |
KR20170054430A (ko) | 2017-05-17 |
RU2017110068A3 (fr) | 2019-08-26 |
US10988531B2 (en) | 2021-04-27 |
EP3188733B1 (fr) | 2019-11-06 |
TW201609152A (zh) | 2016-03-16 |
EP3188733A1 (fr) | 2017-07-12 |
RU2017110068A (ru) | 2018-10-03 |
US11732038B2 (en) | 2023-08-22 |
SG10201901825YA (en) | 2019-03-28 |
KR20240027148A (ko) | 2024-02-29 |
US20160095938A1 (en) | 2016-04-07 |
IL250711A0 (en) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL250711A0 (en) | Conjugates containing cell-binding agents and cytotoxic agents | |
IL290116A (en) | Hydrophilic antibody-drug conjugates | |
HK1231367A1 (zh) | 抗體藥物偶聯物、試劑和製備方法及其治療用途 | |
IL249647A0 (en) | Intended conjugates and particles and their formulations | |
ZA201604824B (en) | Bifunctional cytotoxic agents | |
HK1219422A1 (zh) | 包含細胞結合劑及細胞毒素劑的軛合物 | |
ZA201607385B (en) | Anti-ptk7 antibody-drug conjugates | |
SI3102244T1 (sl) | Konjugati in imunotoksini protitelo-zdravilo | |
PL3102606T3 (pl) | Koniugaty przeciwciało-lek i immunotoksyny | |
ZA201608327B (en) | Curcumin-peptide conjugates and formulations thereof | |
HK1219423A1 (zh) | 包含細胞結合劑及細胞毒素劑的軛合物 | |
IL258759A (en) | Anti-cd3-folate conjugates and their uses | |
GB201615725D0 (en) | Novel cytotoxic agents and conjugates thereof | |
PT3544637T (pt) | Conjugados omv-antigénio nativos e sua utilização | |
EP3143036C0 (fr) | Conjugués thérapeutiques à base de par-1 et utilisations correspondantes |